Garcia Marino received 57,482 derivative securities in AgomAb Therapeutics NV on Sep 11, 2026, leaving the director with 57,482 derivative securities. For investors, the transaction represents about 100.0% of Garcia Marino’s resulting derivative-securities holding, identifying the full position created by the award.

Key Highlights

  • The transaction took place on Sep 11, 2026.
  • The filing identifies transaction code A for the award.
  • The transaction represents about 100.0% of Garcia Marino’s resulting derivative-securities holding.

Garcia Marino received 57,482 derivative securities of AgomAb Therapeutics NV, leaving the director with 57,482 derivative securities after the award. The transaction involved AgomAb Therapeutics NV, identified as AGMB.

AgomAb Derivative Securities Award

The award was recorded under transaction code A. Garcia Marino serves as a director of AgomAb Therapeutics NV. The transaction concerns derivative securities. The reported post-transaction position contains 57,482 derivative securities.

Resulting Position Identified

The awarded amount and the resulting position are both stated at 57,482 derivative securities. The filing states that the transaction represents about 100.0% of Garcia Marino’s resulting derivative-securities holding. Transaction code A denotes an award, grant, or other Acquisition from the company.